BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16140951)

  • 1. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.
    Baranowska-Kortylewicz J; Abe M; Pietras K; Kortylewicz ZP; Kurizaki T; Nearman J; Paulsson J; Mosley RL; Enke CA; Ostman A
    Cancer Res; 2005 Sep; 65(17):7824-31. PubMed ID: 16140951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma.
    Rajkumar VS; Boxer G; Robson M; Muddle J; Papastavrou Y; Pedley RB
    Tumour Biol; 2012 Dec; 33(6):2019-29. PubMed ID: 22833213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer.
    Baranowska-Kortylewicz J; Abe M; Nearman J; Enke CA
    Clin Cancer Res; 2007 Jan; 13(1):299-306. PubMed ID: 17200369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
    Kim R; Emi M; Arihiro K; Tanabe K; Uchida Y; Toge T
    Cancer; 2005 May; 103(9):1800-9. PubMed ID: 15786421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDGFRbeta and HIF-1alpha inhibition with imatinib and radioimmunotherapy of experimental prostate cancer.
    Kimura Y; Inoue K; Abe M; Nearman J; Baranowska-Kortylewicz J
    Cancer Biol Ther; 2007 Nov; 6(11):1763-72. PubMed ID: 17986854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
    Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
    Vlahovic G; Rabbani ZN; Herndon JE; Dewhirst MW; Vujaskovic Z
    Br J Cancer; 2006 Oct; 95(8):1013-9. PubMed ID: 17003785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
    J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
    Wilder RB; Langmuir VK; Mendonca HL; Goris ML; Knox SJ
    Cancer Res; 1993 Jul; 53(13):3022-7. PubMed ID: 8319209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
    Sjöblom T; Shimizu A; O'Brien KP; Pietras K; Dal Cin P; Buchdunger E; Dumanski JP; Ostman A; Heldin CH
    Cancer Res; 2001 Aug; 61(15):5778-83. PubMed ID: 11479215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
    J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a.
    Kurizaki T; Okazaki S; Sanderson SD; Colcher D; Enke CA; Tempero MA; Baranowska-Kortylewicz J
    J Nucl Med; 2002 Jul; 43(7):957-67. PubMed ID: 12097469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors.
    Jain M; Chauhan SC; Singh AP; Venkatraman G; Colcher D; Batra SK
    Cancer Res; 2005 Sep; 65(17):7840-6. PubMed ID: 16140953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.
    Pedley RB; Hill SA; Boxer GM; Flynn AA; Boden R; Watson R; Dearling J; Chaplin DJ; Begent RH
    Cancer Res; 2001 Jun; 61(12):4716-22. PubMed ID: 11406542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
    Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
    Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
    Decaudin D; de Cremoux P; Sastre X; Judde JG; Nemati F; Tran-Perennou C; Fréneaux P; Livartowski A; Pouillart P; Poupon MF
    Int J Cancer; 2005 Feb; 113(5):849-56. PubMed ID: 15499612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
    Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
    J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.